hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal

Digital Asset Direct by hVIVO PLC

London, UK | November 14, 2022 06:14 AM Eastern Standard Time

hVIVO PLC chief executive Mo Khan says "contract values seem to be increasing" for human challenge studies as he updated Proactive after signing a £13.6mln contract with a US-based biopharmaceutical client to test a respiratory syncytial virus (RSV) antiviral drug candidate. He says "we are recruiting more and more subjects into these challenge trials because our clients are seeing the benefits of the challenge study data."

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com